Discovery Laboratories Inc ...nach dem 1:15 R/S

Discovery Labs Announces Reverse Stock Split  
 
Date : 12/27/2010 @ 5:00PM  
Source : GlobeNewswire  Inc.  
Stock : Discovery Laboratories, Inc. (DSCO)  
 
 
 http://ih.advfn.com/...pid=nmona&article=45796169&symbol=DSCO  
 
Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced  that it has filed a Certificate of Amendment to its Amended and Restated  Certificate of Incorporation (the "Amendment") to effect a 1-for-15  share consolidation, or reverse stock split ("reverse split"), effective  at 12:01 a.m. on December 28, 2010 (the "Effective Time"). In  addition, the Amendment reduces the number of shares of common stock,  par value $0.001 per share, authorized under the Certificate of  Incorporation from 380 million to 50 million. Because the  Amendment does not reduce the number of authorized shares of common  stock in the same proportion as the reverse split, the effect of the  Amendment is to increase the number of shares of common stock available  for issuance relative to the number of shares issued and outstanding.  The stockholders of Discovery Labs approved proposals authorizing the  Board of Directors, in its discretion, to implement the reverse split  and reduce the number of authorized shares of common stock at the Annual  Meeting of Stockholders held on December 21, 2010.
 
The Board  of Directors of Discovery Labs has determined to implement the reverse  split at this time to enable the market price per-share of its common  stock to close above $1.00, which is a continued listing requirement of  The NASDAQ Capital Market® ("Nasdaq").  On November 30, 2010, Discovery  Labs received a Staff Determination letter from Nasdaq indicating that  it had not established compliance with Nasdaq Listing Rule 5550(a)(2)  ("Minimum Bid Price Rule") because its common stock had not closed above  $1.00 per share over a period of 10 consecutive business days ending on  or prior to November 29, 2010, and that its stock is subject to  delisting. Discovery Labs has requested a hearing with Nasdaq to review  the Staff Determination and believes that implementation of the reverse  split will support its continued listing on Nasdaq. Discovery Labs  believes that continued listing on Nasdaq, combined with the increase in  shares available for issuance, will enhance its ability to secure  necessary capital from potential strategic partners and prospective  investors to achieve its key business objectives, including potentially  gaining U.S. Food and Drug Administration (FDA) approval for its lead  product, Surfaxin®, for the prevention of respiratory distress syndrome  (RDS) in premature infants.
 
Details of the Reverse Split
 
At the Effective Time, immediately and without further action by  Discovery Labs' stockholders, every 15 shares of Discovery Labs'  pre-split common stock, par value $0.001 per share, will automatically  be converted into one share of post-split common stock, par value $0.001  per share. In lieu of fractional shares, stockholders will receive cash  in an amount equal to the product obtained by multiplying (i) the  closing sale price per share on the business day immediately preceding  the Effective Time as reported on Nasdaq by (ii) the number of shares of  common stock held by the stockholder that would otherwise have been  exchanged for the fractional share interest.
 
The immediate  effect of the reverse split will be to reduce the number of shares of  Discovery Labs' common stock that are issued and outstanding to  approximately 13.8 million shares (excluding shares reserved for  stock options and unexercised warrants), adjusted for fractional  interests. The reverse split will affect all stockholders uniformly and  will have no effect on the proportionate holdings of any individual  stockholder, with the exception of adjustments related to fractional  shares. There will be no change in the number of stockholders of record  as a result of the reverse split. Following the reverse split, all  shares will remain fully paid and non-assessable.
 
To inform  the market of the reverse split, Discovery Labs expects that Nasdaq will  append a suffix character, "D," to the Company's trading symbol (DSCO)  for approximately 20 days after the Effective Time.  After the ~20  trading-day period, the ticker symbol will revert to "DSCO".  In  addition, Discovery Labs' common stock will also trade under a new CUSIP  number beginning on December 28, 2010.
 
Additional  information can be found in Discovery Labs' definitive proxy statement,  which was filed with the SEC on November 15, 2010 and is available on  the Company's website at www.Discoverylabs.com.

investorshub.advfn.com/boards/board.aspx

Pipeline Overview

www.discoverylabs.com/poverview.php

Discovery Labs is developing its novel, fully synthetic KL4 Surfactant  platform with the intent to create a completely new therapeutic approach for the  treatment of respiratory disease.

Neonatology  

Product introduction begins with anticipated US FDA approval of SURFAXIN^® (lucinactant), a  liquid instillate formulation of KL4 Surfactant, for Respiratory Distress  Syndrome (RDS) in premature infants.

Discovery Labs is developing multiple product solutions for RDS, supporting  KL4 Surfactant delivery through a variety of dosage forms, including SURFAXIN LS^™, a lyophilized  formulation of KL4 Surfactant as well as AEROSURF^®, aerosolized KL4 Surfactant.  AEROSURF^® represents a transformational approach toward neonatal  respiratory critical care by potentially reducing or eliminating complications  associated with mechanical ventilation.

 Additional Respiratory  Applications  

Discovery Labs is also advancing KL4 Surfactant development in other  respiratory disease areas. Key areas of interest include Mucociliary Clearance Dysfunction, a condition which is common  to many respiratory diseases; Respiratory  Critical Care Spectrum disorders, which include Acute Respiratory Failure  (ARF), Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS);  and the use of our KL4 Surfactant as an aerosol liposomal system enabling a  novel Drug Delivery mechanism for  complex pharmaceutical compounds.

hier ist doch das selbe Spiel wie bei Genta. DSCO kennt auch nur RS und KE.